秦本军先生及公司已与本次交易的主要交易对方广州德福营养、德福金康普控股有限合伙企业、厦 门德福金普投资合伙企业（有限合伙）分别签署了《控制权变更意向协议》《发行股份购买资产并募集 配套资金意向协议》，协议约定秦本军先生通过协议转让方式将其所持有的部分公司股份转让给广州德 福营养，并签署《表决权放弃协议》，自愿放弃其所持公司部分股份的表决权。同时公司拟向德福金康 普控股有限合伙企业和厦门德福金普投资合伙企业（有限合伙）发行股份购买其合计持有的北京金康普 80%股权，以及向广州德福营养发行股份募集配套资金。 交易标的相关股权的最终交易价格，以公司聘请的符合证券法规定的评估机构出具的评估报告结果 为定价依据，由交易各方协商确定。上述协议仅为交易各方就本次交易达成的初步意向，本次交易的具 体方案将由交易各方另行签署正式协议予以约定。 因上述交易尚处于筹划阶段，有关事项存在不确定性，为保证信息披露的公平，维护投资者利益， 避免对公司股票交易造成重大影响，根据《深圳证券交易所上市公司自律监管指引第6号—停复牌》等 有关规定，经公司申请，公司股票（证券简称：莱茵生物，证券代码：002166）自2025年12月10日（星 期 ...

明起停牌。 莱茵生物（002166）12月9日晚间公告，公司于2025年12月8日收到控股股东、实际控制人秦本军的通知，秦本军正在筹划公司控制权变更 事宜。公司股票自2025年12月10日开市起停牌，预计停牌时间不超过10个交易日。 公告显示，秦本军及公司已与本次交易的主要交易对方广州德福营养投资合伙企业（有限合伙）（简称"广州德福营养"）、德福金康普控 股有限合伙企业、厦门德福金普投资合伙企业（有限合伙）分别签署了《控制权变更意向协议》《发行股份购买资产并募集配套资金意向 协议》，协议约定秦本军通过协议转让方式将其所持有的部分公司股份转让给广州德福营养，并签署《表决权放弃协议》，自愿放弃其所 持公司部分股份的表决权。上述事项可能导致公司控股股东及实际控制人发生变更。 同时公司拟向德福金康普控股有限合伙企业和厦门德福金普投资合伙企业（有限合伙）发行股份购买其合计持有的北京金康普食品科技有 限公司（简称"北京金康普"）80%股权，以及向广州德福营养发行股份募集配套资金。 本次交易完成后，北京金康普将成为公司的控股子公司，纳入合并财务报表范围。本次交易不构成重大资产重组及重组上市。 本次交易将北京金康普纳入上市公 ...

Core Viewpoint - Rhine Biotech (002166) announced a suspension of its stock trading starting December 10 due to plans for a change in control, issuance of shares, and cash payment for asset acquisition, with the suspension expected to last no more than 10 trading days [1] Group 1: Control Change - The controlling shareholder and actual controller, Qin Benjun, is planning to transfer part of his shares and relinquish voting rights [1] - A "Control Change Intent Agreement" has been signed with the counterparty, Guangzhou Defu Nutrition Investment Partnership (Limited Partnership) [1] Group 2: Acquisition Details - Rhine Biotech intends to acquire at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a combination of share issuance and cash payment [1] - Following the transaction, Beijing Jinkangpu will become a subsidiary of Rhine Biotech and will be included in the consolidated financial statements [1] - The transaction is not classified as a major asset restructuring or restructuring listing, but it is expected to constitute a related party transaction [1] Group 3: Company Background - Beijing Jinkangpu, established in 2004, specializes in the compounding, testing, sales, and technical development of food nutrition fortifiers [1] - Rhine Biotech's core products include natural sweeteners [1]

Core Viewpoint - Tai Long Pharmaceutical (600222.SH) has resumed trading after a significant shareholder change, with shares closing at 8.20 yuan, down 4.43%, and a total market capitalization of 4.706 billion yuan [1] Group 1: Shareholder Change and Stock Resumption - The company announced that its controlling shareholder, Tai Rong Chan Investment, is planning a share transfer that may lead to a change in control [1] - The stock was suspended from trading on December 2, 2025, and initially expected to resume on December 4, but continued to be suspended until December 9, 2025 [1] - The resumption of trading occurred after an agreement was reached regarding the share transfer [1] Group 2: A-Share Issuance - The company plans to issue A-shares to specific investors, aiming to raise up to 454.35 million yuan, which will be used for working capital and repaying interest-bearing debts [2] - The shares will be issued at a price of 6.09 yuan per share, which is not less than 80% of the average trading price over the previous 20 trading days [3] - The issuance will involve a maximum of 74,605,216 shares, representing 13% of the total share capital before the issuance [3] Group 3: Share Transfer Agreement - On December 8, 2025, Jiang Pharmaceutical Holdings signed a share transfer agreement with Tai Rong Chan Investment to acquire 50,100,000 shares, which is 8.73% of the total share capital before the issuance [4] - The share transfer will occur in two tranches, with the first tranche involving 42,300,000 shares and the second tranche involving 7,800,000 shares [4] - An action agreement was also signed, ensuring that Tai Rong Chan Investment and Jiang Pharmaceutical Holdings will act in concert regarding major decisions affecting the company [4] Group 4: Control Changes - Following the completion of the first share transfer and the action agreement, Jiang Pharmaceutical Holdings will become the controlling shareholder, with the actual controller being the Jiangxi Provincial State-owned Assets Supervision and Administration Commission [5] - Jiang Pharmaceutical Holdings will hold 42,300,000 shares, while Tai Rong Chan Investment will retain 40,141,168 shares, giving them a combined control of 82,441,168 shares, or 14.37% of the total share capital [6] - The issuance of A-shares to Jiang Pharmaceutical Holdings will not change the control of the company, as they will remain the controlling shareholder [6]

在酒店业竞争日益激烈的背景下，一场涉及控制权变更的重磅交易浮出水面。 日前，君亭酒店集团股份有限公司（301073.SZ，以下简称"君亭酒店"）发布公告，湖北省文化旅游集团有限公司（以下简称"湖北文旅"）拟以总计约18亿 元的资金，通过协议转让和部分要约收购的方式，取得公司控股权。 交易完成后，这家知名的中高端酒店品牌将从一家民营企业转变为湖北省国资委实际控制的国有控股企业。 根据公告，此次交易分为两个部分。首先，湖北文旅将以每股25.71元的价格，受让公司创始人吴启元及其一致行动人持有的近30%股份，转让总价款约为 14.99亿元。作为交易安排的一部分，现年81岁的创始人吴启元还将放弃其剩余部分股份的表决权。紧接着，湖北文旅将向全体股东发起要约收购，计划进 一步增持约6.01%的股份。 若交易顺利完成，湖北文旅将合计持有君亭酒店36%的股份及对应表决权，成为新的控股股东。 对于此次控制权变更，湖北文旅在公告中明确表示，旨在为君亭酒店注入优质资源，改善其经营业绩，并解决公司"持续投入能力不足的短板"。这一表态直 接指向了君亭酒店当前面临的现实压力。 今年以来，国内酒店市场供需结构阶段性失衡，行业竞争加剧，导致 ...

Group 1: National Medical Insurance Directory Inclusion - Heng Rui Medicine has multiple drugs included in the 2025 National Medical Insurance Directory [1] - Xing Qi Eye Medicine has 39 products continuing to be included in the National Medical Insurance Drug Directory [1] - Bei Da Pharmaceutical has four products included in the National Medical Insurance Drug Directory [1] - Junshi Biosciences has added indications for Tuoyi® and included Junshida® in the National Medical Insurance Directory [1] - Zhongsheng Pharmaceutical's innovative drug Angladiwei tablets have been included in the National Medical Insurance Directory through negotiation [1] - Yiling Pharmaceutical's subsidiary has its exclusive product Qifang Nasal Tablets included in the National Medical Insurance Directory, totaling 12 exclusive patented traditional Chinese medicine products [1] - Aosaikang's product Liratinib tablets (Aoyi Xin®) has been included in the 2025 National Medical Insurance Directory [1] - Kanghong Pharmaceutical's product Kangbai Xip eye injection (Langmu) has been included in the 2025 National Medical Insurance Directory [1] - Dongcheng Pharmaceutical's Technetium-99m injection has been included in the medical insurance directory; its subsidiary has received clinical trial approval for 177Lu-LNC1009 injection [1] - Micron Biomedical's Sidabena tablets have been included in the National Medical Insurance Directory for regular Class B management [1] - Haichuang Pharmaceutical's Deuteroenzalutamide soft capsules have been included in the National Medical Insurance Directory for the first time [1] - Huadong Medicine's subsidiary products and cooperative products have been included in the National Medical Insurance and commercial insurance innovative drug directory [1] - Aidi Pharmaceutical's two anti-HIV innovative drugs continue to be included in the National Medical Insurance Directory through a simplified renewal process [1] Group 2: Corporate Developments - Hengyin Technology has signed a cooperation agreement with Muxi Co., focusing on the domestic GPU scenario [1] - Jia Jian Co. is planning a change in control, with stock resuming trading on December 8 [2] - Gu Ao Technology's actual controller is planning a change in control, leading to stock suspension [2] Group 3: Financial Performance - Tianbang Food reported a commodity pig sales revenue of 654 million yuan in November, a month-on-month increase of 7.66% [3] - Tian Ci Materials' controlling shareholder has committed not to reduce company shares [3]

Group 1: JiaHua Technology Acquisition - JiaHua Technology plans to acquire 90% of ShuDun Technology, which is expected to constitute a major asset restructuring, with stock resuming trading on December 8 [1][2] - The acquisition will be executed through a combination of issuing shares and cash payments, involving 49 transaction parties [2] - ShuDun Technology specializes in password technology and provides comprehensive information security solutions across various sectors, including energy and transportation [2][3] Group 2: Financial Performance of JiaHua Technology - In 2024, JiaHua Technology's revenue is projected to be 300 million yuan, a decrease of 6.81% year-on-year, with a net loss of 103 million yuan compared to a loss of 208 million yuan in the previous year [3] - For the first three quarters of 2025, the revenue is expected to be 166 million yuan, down 30.72% year-on-year, with a net loss of 67 million yuan compared to a loss of 31 million yuan in the same period last year [3] Group 3: Announcements from Other Companies - Annie Co. announced a change in its controlling shareholder to Shengshi Tianan, with a total of 92.29 million shares transferred, representing 15.92% of the company's total share capital [4][5] - ST Tianrui has terminated its plans for a change in control due to a lack of consensus among major stakeholders, with stock resuming trading on December 8 [7]

韶能股份表示，此次交易预计将有助于公司盘活资产、提升经营效率。鉴于本次以公开挂牌方式转让标的资产，处置完成情况存在不确定性，预计获得的 损益及对公司本期和未来财务状况和经营成果的影响暂无法确定，具体影响金额以处置完成后会计师年度审计结果为准。 12月5日晚间，韶能股份（000601）发布公告称，为优化业务结构，提升经营效率，降低管理成本，回笼资金聚焦主业发展，公司拟将名下15处房产对外 公开挂牌转让。经韶关市鼎顺房地产与土地评估有限公司评估，这批房产评估总价为1654.70万元，公开挂牌转让价以评估价为基础，最终以实际成交价 为准。 公告显示，公司此次拟出售的15处房产均位于韶关市。从分布来看，标的资产集中于韶关市核心区域，其中武江区占比较高，涵盖工业中路、芙蓉北路等 地段，韶关市浈江区十里亭镇靖村也有3处资产纳入处置范围。房产用途包括住宅、非住宅、办公等。 据公告，公司本次拟出售的15处房产总计面积为13358.17平方米，按照1654.7万元的最终评估值来计算，每平米的均价仅1238.72元。 公司称，本次拟挂牌交易的房产不存在抵押、质押或者其他第三人权利，不存在涉及重大争议、诉讼或仲裁事项，不存在查封、 ...

近三年连续亏损 古鳌科技是专业的智慧金融系统整体解决方案和金融软件信息化产品的供应商和服务商，主营业务有金 融设备业务、金融衍生品业务等，客户涵盖银行、证券公司、期货公司、公募、私募等金融机构。 不过，自2016年上市以来，古鳌科技净利润总体呈下滑态势，2022年至2024年连续三年亏损，2025年前 三季度继续亏损约1.64亿元。 中国基金报记者 卢鸰 古鳌科技12月7日公告，公司近日收到实际控制人陈崇军配偶的书面通知，获悉公司实际控制人陈崇军 正在筹划公司控制权变更事项，该事项可能导致公司实际控制人变更。目前，各方主体正在就具体交易 方案、协议等相关事项进行论证和磋商。 鉴于上述事项尚存在重大不确定性，为保证公平信息披露，根据相关规定，经古鳌科技向深圳证券交易 所申请，公司股票自2025年12月8日（星期一）开市起停牌，预计停牌时间不超过2个交易日。 12月5日，古鳌科技股价以13.7元/股报收，大涨8.9%，市值为46.6亿元。 （原标题：300551，筹划控制权变更！紧急停牌） 【导读】古鳌科技公告，公司实际控制人陈崇军正在筹划公司控制权变更事项 上海昊元古持有新存科技24.8432%股权 新存科技由 ...

Group 1 - The core viewpoint of the articles revolves around significant asset restructuring activities involving multiple companies, particularly Jiahua Technology's acquisition of 90% of Shudun Technology, which is expected to enhance its market competitiveness and product offerings [1][2][3] - Jiahua Technology's stock will resume trading on December 8 after being suspended since November 24 due to the announcement of the major asset restructuring [2] - Jiahua Technology's revenue for 2024 is projected to be 300 million yuan, a decrease of 6.81% year-on-year, with a net loss of 103 million yuan compared to a loss of 208 million yuan in the previous year [3] Group 2 - Annie Co. announced a change in its controlling shareholder to Shengshi Tianan, with a total of 92.29 million shares transferred, representing 15.92% of the company's total share capital [5][6] - The share transfer price was set at 8.3610 yuan per share, totaling 772 million yuan, and the new controlling shareholders are expected to optimize the company's management and resource allocation [6][7] - ST Tianrui has decided to terminate its planned change of control due to a lack of consensus among the parties involved, and its stock will also resume trading on December 8 [8]